SOX9 and glioblastoma: Conclusively, PXN‐AS1 acts as an oncogene in GBM, and SOX9‐activated PXN‐AS1 promotes GBM progression by epigenetically silencing DKK1, suggesting a helpful revelation for the exploration of novel GBM diagnostic and therapeutic strategies.